We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+25.44%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.62B
AUM Growth
+$266M
(+20%)
Cap. Flow
-$127M
Cap. Flow
% of AUM
-7.84%
Top 10 Holdings %
Top 10 Hldgs %
60.86%
Holding
43
New
3
Increased
6
Reduced
5
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VERV
Verve Therapeutics
VERV
|
+$24.8M |
| 2 |
CRGX
CARGO Therapeutics
CRGX
|
+$21.2M |
| 3 |
Lexeo Therapeutics
LXEO
|
+$16.2M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$4.59M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$4.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$51.2M |
| 2 |
ACLX
Arcellx
ACLX
|
+$38.6M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$33.9M |
| 4 |
Corcept Therapeutics
CORT
|
+$26.5M |
| 5 |
OKUR
OnKure Therapeutics
OKUR
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.2% |
| 2 | Technology | 25.25% |
| 3 | Financials | 11.17% |
| 4 | Industrials | 4.91% |
| 5 | Communication Services | 4.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Brookfield
BN
$102B
| $156M | 9.61% |
5,820,345
| – | – |
|
2
ASML
ASML
$596B
| $150M | 9.24% |
197,760
| – | – |
|
3
Salesforce
CRM
$154B
| $140M | 8.62% |
530,500
| – | – |
|
4
Spero Therapeutics
SPRO
$68.9M
| $123M | 7.62% |
468,902
| – | – |
|
5
LanzaTech
LNZA
$59.9M
| $79.5M | 4.91% |
158,148
| – | – |
|
|
6
Corcept Therapeutics
CORT
$9.98B
| $78.3M | 4.84% |
2,411,362
-966,406
| -29% | -$26.5M |
|
7
TSMC
TSM
$1.94T
| $73.9M | 4.56% |
710,780
| – | – |
|
8
Edgewise Therapeutics
EWTX
$4.28B
| $66.4M | 4.1% |
6,071,703
| – | – |
|
9
Cable One
CABO
$237M
| $65.9M | 4.07% |
118,403
| – | – |
|
10
Vaxcyte
PCVX
$7.65B
| $53.1M | 3.28% |
845,000
| – | – |
|
11
Mirum Pharmaceuticals
MIRM
$6.56B
| $44.3M | 2.73% |
1,500,000
| – | – |
|
|
12
BioMarin Pharmaceuticals
BMRN
$11.9B
| $43.4M | 2.68% |
450,000
+50,000
| +13% | +$4.42M |
|
13
Pharvaris
PHVS
$2.28B
| $43.2M | 2.67% |
1,539,325
+210,000
| +16% | +$4.25M |
|
14
Apple
AAPL
$4.97T
| $42.6M | 2.63% |
221,460
| – | – |
|
15
Insmed
INSM
$22.4B
| $41.5M | 2.56% |
1,339,304
| – | – |
|
16
Crinetics Pharmaceuticals
CRNX
$8.88B
| $39.1M | 2.42% |
1,100,000
| – | – |
|
17
Alibaba
BABA
$276B
| $38.8M | 2.4% |
500,827
| – | – |
|
|
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
| $35.5M | 2.19% |
2,500,000
+404,100
| +19% | +$4.59M |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $33.1M | 2.05% |
359,126
-165,874
| -32% | -$10.7M |
|
20
Rocket Pharmaceuticals
RCKT
$343M
| $31.5M | 1.94% |
1,050,000
+49,000
| +5% | +$1.08M |
|
21
4D Molecular Therapeutics
FDMT
$502M
| $30.4M | 1.88% |
1,500,000
+300,000
| +25% | +$3.95M |
|
|
CRGX
22
DELISTED
CARGO Therapeutics
CRGX
| $28.9M | 1.79% |
+1,250,000
| New | +$21.2M |
|
|
VERV
23
DELISTED
Verve Therapeutics
VERV
| $27.9M | 1.72% |
+2,000,000
| New | +$24.8M |
|
24
Brookfield Asset Management
BAM
$75.6B
| $25.2M | 1.56% |
627,207
| – | – |
|
25
Alnylam Pharmaceuticals
ALNY
$38.3B
| $22.7M | 1.4% |
118,383
| – | – |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q4 2023 Portfolio in Review
As of Q4 2023, Novo Holdings A/S held 43 positions worth $1.62B, up 20% from $1.35B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Novo Holdings A/S withdrew a net $127M in Q4 2023, closing 7 positions and reducing 5 holdings. Its most notable exit was Disc Medicine, an estimated $51.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 51% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S opened a new position in Verve Therapeutics worth $27.9M.
- Novo Holdings A/S's largest Q4 2023 buy was Verve Therapeutics: 2,000,000 shares worth $27.9M.
- Novo Holdings A/S added most to Amicus Therapeutics in Q4 2023, an estimated $4.59M increase.
- Novo Holdings A/S's biggest Q4 2023 reduction was Corcept Therapeutics, cutting an estimated $26.5M.
- Novo Holdings A/S fully exited Disc Medicine in Q4 2023, selling an estimated $51.2M.
- Novo Holdings A/S's ten largest holdings make up 61% of its $1.62B portfolio in Q4 2023.
- Novo Holdings A/S opened 3 new positions and closed 7 in Q4 2023.
- Novo Holdings A/S's portfolio value rose 20% quarter-over-quarter to $1.62B.
Based on Novo Holdings A/S's 13F filing for Q4 2023, filed 14 Feb 2024.